A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study of belimumab in patients with active systemic lupus erythematosus
Arthritis Care & Research · 15.09.2009 · 61 (9) · 1168-1178
DOI: 10.1002/art.24699 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Arthritis Care & Research, online erschienen am 27.08.2009. Verfasst von Daniel J Wallace und 13 weiteren Autor:innen. Beteiligte Einrichtung: Cedars-Sinai Medical Center, University of California, Los Angeles, USA. Hauptthemen laut MEDLINE: Severity of Illness Index. Die Arbeit wurde bisher 514-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCRR NIH HHS.
Abstract (Originalsprache)
Objective
To assess the safety, tolerability, biologic activity, and efficacy of belimumab in combination with standard of care therapy (SOC) in patients with active systemic lupus erythematosus (SLE).
Methods
Patients with a Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA) version of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score ≥4 (n = 449) were randomly assigned to belimumab (1, 4, or 10 mg/kg) or placebo in a 52‐week study. Coprimary end points were the percent change in the SELENA–SLEDAI score at week 24 and the time to first SLE flare.
Results
Significant differences between the treatment and placebo groups were not attained for either primary end point, and no dose response was observed. Reductions in SELENA–SLEDAI scores from baseline were 19.5% in the combined belimumab group versus 17.2% in the placebo group. The median time to first SLE flare was 67 days in the combined belimumab group versus 83 days in the placebo group. However, the median time to first SLE flare during weeks 24–52 was significantly longer with belimumab treatment (154 versus 108 days; P = 0.0361). In the subgroup (71.5%) of serologically active patients (antinuclear antibody titer ≥1:80 and/or anti–double‐stranded DNA [anti‐dsDNA] ≥30 IU/ml), belimumab treatment resulted in significantly better responses at week 52 than placebo for SELENA–SLEDAI score (−28.8% versus −14.2%; P = 0.0435), physician's global assessment (−32.7% versus −10.7%; P = 0.0011), and Short Form 36 physical component score (+3.0 versus +1.2 points; P = 0.0410). Treatment with belimumab resulted in a 63–71% reduction of naive, activated, and plasmacytoid CD20+ B cells, and a 29.4% reduction in anti‐dsDNA titers ( P = 0.0017) by week 52. The rates of adverse events and serious adverse events were similar in the belimumab and placebo groups.
Conclusion
Belimumab was biologically active and well tolerated. The effect of belimumab on the reduction of SLE disease activity or flares was not significant. However, serologically active SLE patients responded significantly better to belimumab therapy plus SOC than to SOC alone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Cedars-Sinai Medical Center, University of California, Los Angeles, USA.
Förderung
- NCRR NIH HHS
Zitieren
APA
Wallace, D. J., Stohl, W., Furie, R. A., Lisse, J. R., McKay, J. D., Merrill, J. T., Petri, M. A., Ginzler, E. M., Chatham, W. W., McCune, W. J., Fernandez, V., Chevrier, M. R., Zhong, Z. J., & Freimuth, W. W. (2009). A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Care & Research, 61(9), 1168-1178. https://doi.org/10.1002/art.24699
Vancouver
Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, et al. A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Care & Research. 2009;61(9):1168-1178. doi:10.1002/art.24699
BibTeX
@article{Wallace2009,
author = {Wallace, Daniel J and Stohl, William and Furie, Richard A and Lisse, Jeffrey R and McKay, James D and Merrill, Joan T and Petri, Michelle A and Ginzler, Ellen M and Chatham, W Winn and McCune, W Joseph and Fernandez, Vivian and Chevrier, Marc R and Zhong, Z John and Freimuth, William W},
title = {A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study of belimumab in patients with active systemic lupus erythematosus},
journal = {Arthritis Care & Research},
year = {2009},
volume = {61},
number = {9},
pages = {1168--1178},
doi = {10.1002/art.24699}
}
EUVIMED